Borderline Resectable Pancreatic Ductal Adenocarcinoma
11 clinical trials · Condition
◉ Watch Borderline Resectable Pancreatic Ductal Adenocarcinoma
| Record | Firm | Date |
|---|---|---|
| Targeted Pathway Inhibition in Patients With Pancreatic Cancer (NCT04005690) | OHSU Knight Cancer Institute | 2019-08-01 |
Track Borderline Resectable Pancreatic Ductal Adenocarcinoma automatically
Every clearance here is in the API, with alerts when new ones post.